News Headlines

  1. Octane Medical Group Signs Agreement To Acquire Lonza's Personalized Medicine Business 3/4/2026

     Octane Medical Group ("Octane") today announced that it has entered into a definitive agreement to acquire Lonza's Personalized Medicine business. For Octane, this is a strategically significant deal that comprises Lonza's controlling stake in the Cocoon® Platform – originally acquired from Octane in 2018 – alongside associated intellectual property (IP), workforce and existing customer contracts.

  2. Lifecore Biomedical Signs New Agreement With Indomo To Support Innovative Drug/Device Combination Acne Treatment 3/4/2026

    Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), and Indomo, a clinical-stage company dedicated to expanding access to quality healthcare via innovative device-enabled therapeutics, today announced that the companies have entered into a new development services agreement through which Lifecore will provide Indomo with a range of CDMO services to support the continued development of its corticosteroid drug candidate, DT-001.

  3. BioMed Realty And CordenPharma Colorado Team Up For Expansion Of Peptide Development Lab In New LEED Gold-Certified Facility At Flatiron Park In Boulder 3/4/2026

    BioMed Realty, the largest private owner and operator of real estate for the life science, technology and innovation industries, announced that CordenPharma Colorado, a leading peptide drug substance Contract Development and Manufacturing Organization (CDMO), has leased 64,000 square feet at Flatiron Park’s 5505 Central – Boulder’s first purpose-built speculative lab building – near the existing CordenPharma Colorado facility.

  4. BioDuro And Cenra Launch Joint Venture To Expand Resilient Global API Manufacturing Capacity 3/3/2026

    BioDuro, a globally trusted Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has established a joint venture with Cenra API Solutions, also as known as Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB), a leading pharmaceutical chemical manufacturer in Taiwan since 1964, to add significant commercial-scale active pharmaceutical ingredient (API) manufacturing capacity at Cenra's campus in Taipei, Taiwan, to BioDuro's global network.

  5. Adial Pharmaceuticals Signs An Exclusive AD04 Collaboration Framework With Molteni Farmaceutici For Europe Which Anticipates Nearly $60M In Potential Royalties And Milestones Upon execution Of A Definitive Agreement 3/3/2026

    Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders, today announced it has entered into a collaboration framework agreement with Molteni Farmaceutici (“Molteni”) for a proposed exclusive partnership covering the commercialization of AD04 in Europe.

  6. UCB And Antengene Enter Global License Agreement For ATG-201, A B Cell-Depleting Bispecific Antibody 3/3/2026

    UCB, a global biopharmaceutical company, and Antengene Corporation Limited (Antengene), an innovative, commercial-stage global biotech company today announced that they have entered into an agreement that grants UCB a worldwide exclusive license to further develop, manufacture and commercialize ATG-201 and access to its associated manufacturing technology in relation to ATG-201.

  7. Aspire Biopharma Partners With Microsize To Develop Rapid-Delivery Sublingual Powder Formulation Of Alprazolam For Faster Anxiety Relief 3/3/2026

    Aspire Biopharma Holdings, Inc. ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted, patent-pending drug delivery technology, today announced a strategic partnership with Microsize (Quakertown, Pennsylvania), the largest independent North American contract development and manufacturing organization (CDMO) focused on cGMP micronization and particle size engineering.

  8. The Progeria Research Foundation And Forge Biologics Announce Manufacturing Partnership To Advance Gene Therapy For Children With Progeria 3/3/2026

    The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and Forge Biologics, (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced a manufacturing agreement to support the development and manufacturing of SamPro-2, PRF’s investigational gene therapy for children and young adults living with Progeria, an ultrarare and fatal genetic disease characterized by rapid aging.

  9. FUJIFILM Biotechnologies Unveils ShunzymeX Precision Purification Technology 3/3/2026

    FUJIFILM Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today unveils ShunzymeX precision purification technology, which simplifies downstream processing for complex biologics.

  10. Cure Rare Disease And LGMD2L Foundation Announce Multi-Year Partnership To Develop Gene Therapy For Anoctamin 5-Related Disease 3/2/2026

    Cure Rare Disease (CRD), a non-profit biotechnology organization, today announced a landmark partnership with the LGMD2L Foundation.